PubMed Health⌕ Search

Biomedical subjects

M Applebaum

Publications and source records attributed to M Applebaum.

25 records · Page 2Linked to original sources
PubMed1983

Use of diagnostic pharmaceutical agents and incidence of adverse effects.

A drug registry was established at Southern California College of Optometry (SCCO) to study use rates and incidence of adverse side effects of the nine pharmaceutical agents in the California optometry law. Data were gathered in clinics of SCCO for 6 months and offices of 20 private practitioners for 3 months. Data included drugs used, the strength and dosage, patient age, sex, and racial or ethnic origin. Adverse drug reactions were reported in detail, including objective and subjective findings, duration of the reaction, and case disposition. A total of 12,493 drug applications were reported. A low incidence of adverse reactions, eight cases (0.208%), which produced no permanent effects, is sound evidence regarding the risk/benefit ratio in support of the use of pharmaceutical agents by optometrists.

Adolescent↗
PubMed1982

Development of a standardized data base for clinical evaluation.

This paper offers a frank discussion of the difficulties involved in developing a standardized data base. These difficulties include: agreement on diagnostic coding, compliance in input of data, philosophical differences among the schools and colleges of optometry, assessment of clinical competence, and comparison among institutions.

Clinical Competence↗
PubMed1980

Drug toxicity and visual fields.

Many drugs used in the treatment of systemic pathologies may cause retinal or neurotoxic side effects which effect visual fields. This paper discusses the role of the drug history, personal health history, and testing procedures in evaluating these toxic visual fields. Specific drugs are cited which may cause toxic visual field defects.

Color Perception↗
PubMed1975

Abnormalities of carbamyl phosphate synthetase and ornithine transcarbamylase in liver of patients with Reye's syndrome.

Urea cycle function was evaluated in liver obtained from six patients with Reye's syndrome and from five control subjects. Reye's syndrome patients demonstrated normal activities for the extramitochondrial portion of the urea cycle, but showed marked abnormalities of the mitochondrial enzymes, i.e., carbamyl phosphate synthetase (CPS) and ornithine transcarbamylase (OTC) (Tables 2,3). CPS activity was reduced to less than 15% of control values in all four patients from whom tissues was obtained during the first 72 hr after the onset of encephalopathy. Two patents from whom tissue was not obtained until after 9 days of symptoms showed no reduction in CPS activity. The OTC activity was also reduced (3-67% of control values) in the four patients from whom tissue was obtained early in the illness. In addition, greater than 60% reduction in Vmax and Km for carbamyl phosphate was noted in all four patients in whom sample size permitted kinetic analysis, including both patients in whom CPS and OTC activity were not markedly reduced. The same kinetic abnormality as well as decreased CPS activity were experimentally produced in normal rate liver incubated in the presence of 1.0 mM 4-pentenoic acid, a short chain fatty acid and known hepatic mitochondrial toxin (Table 4).

Animals↗